A Look At Clover Health (CLOV) Valuation After Recent Share Price Momentum

Recent performance context

Clover Health Investments (CLOV) has drawn attention after a sharp share price move, with the stock closing at US$3.99. Investors are considering this in light of its recent returns and its ongoing Medicare Advantage focused business.

See our latest analysis for Clover Health Investments.

The latest 1 day share price return of 9.32% comes after a softer 7 day share price return of 4.55%. However, the 30 day share price return of 52.87% and 90 day share price return of 99.5% suggest momentum has been building, while the 1 year total shareholder return of 32.12% contrasts with a very large 3 year total shareholder return and a 5 year total shareholder return that remains significantly lower.

If you are looking beyond Clover Health Investments for ideas in a similar space, this is a good moment to scan for other healthcare related AI opportunities using the 40 healthcare AI stocks.

With Clover Health Investments now at US$3.99 after strong recent gains, investors are asking whether the share price still lags its estimated intrinsic value, or if the market is already pricing in future growth potential.

Most Popular Narrative: 27% Overvalued

Compared with the most widely followed fair value estimate of $3.15, Clover Health Investments at $3.99 sits above that narrative-based value and puts a spotlight on the earnings path analysts are using to justify their models.

Analysts expect earnings to reach $30.9 million (and earnings per share of $0.05) by about June 2029, up from $56.9 million in losses today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $66.3 million in earnings, and the most bearish expecting $25.5 million.

Read the complete narrative.

Want to see what sits behind that swing from losses to positive earnings and a higher future earnings multiple? The narrative leans heavily on faster revenue growth, slimmer loss ratios, and a specific profit margin target that has to hold together over multiple years.

Result: Fair Value of $3.15 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that earnings swing still depends on assumptions that medical costs remain contained and that Medicare Advantage reimbursement or policy changes do not erode future margins.

Find out about the key risks to this Clover Health Investments narrative.

Another angle on valuation

The analyst narrative flags Clover Health Investments as 27% overvalued at $3.99 versus a $3.15 fair value, yet our DCF model points the other way and indicates the stock is trading about 88% below its estimated future cash flow value of $32.42. Which framework do you trust more when expectations are this far apart?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With sentiment clearly mixed, this is the moment to look through the numbers yourself and decide how you feel about the balance of risks and rewards, starting with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you miss plenty of opportunities. Keep expanding your watchlist so you always have fresh candidates ready for your next move.

• Spot potential turnaround stories early by scanning 24 elite penny stocks with strong financials that already show stronger financials than many expect from low priced stocks.
• Zero in on quality at a reasonable price by checking the 47 high quality undervalued stocks that combine solid balance sheets with healthier cash flows.
• Dial back portfolio stress by reviewing 64 resilient stocks with low risk scores that aim for more resilient business profiles and fewer unpleasant surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com